AT108 / Asgard Therapeutics - LARVOL DELTA

Optimized in situ tumor-to-dendritic cell reprogramming by AT-108 adenoviral vector drives local and systemic antitumor immunity. (ASGCT 2026) - "Combination with ICB further amplified lymphocyte infiltration. Conclusion These findings show that AT-108 induces systemic, dose-dependent efficacy with activity across distinct tumor microenvironments and highlights key biomarker parameters to explore in a future clinical trial."

IO biomarker • Viral vector • Oncology • BATF3 • IRF8

Preclinical efficacy and biomarker characterization of a first-in-class in situ tumor-to-dendritic cell reprogramming agent (CIMT 2026) - "Flow cytometry confirmed increased effector/cytotoxic T cells, follicular helper T cells and DCs in tumors and blood, identifying candidate pharmacodynamic markers for AT-108 activity. These findings show that AT-108 induces systemic, dose-dependent efficacy in non-immunogenic tumor microenvironments and highlights key biomarker parameters to explore in a future clinical trial."

IO biomarker • Preclinical • Oncology • BATF3 • IRF8

Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent (AACR 2026) - "Monotherapy efficacy was associated with detectable transgene expression in B16 tumors and increased effector/cytotoxic T cells, follicular helper T cells and dendritic cells in tumors and blood, identifying candidate pharmacodynamic markers for AT-108. Combination with ICB further amplified lymphocyte infiltration.These findings show that AT-108 induces systemic, dose-dependent efficacy with broad activity across distinct tumor microenvironments and highlights key biomarker parameters to explore in a future clinical trial."

IO biomarker • Late-breaking abstract • Preclinical • Oncology • BATF3 • IRF8

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026 (GlobeNewswire) - "The poster presentation, titled 'Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent’, will detail preclinical data demonstrating that AT-108 induces systemic, dose-dependent efficacy with broad tumor activity. Key biomarker parameters were highlighted to be explored in future clinical development."

Preclinical • Oncology

A cancer immunotherapy modality based on dendritic cell reprogramming in vivo (ESGCT 2024) - "Finally, CR mice treated with Ad-PIB mounted long-term immune memory, remained tumor-free for 160 days and were protected against local and metastatic colonization after subcutaneous and intravenous re-challenges. Together, our study paves the way for the first-in-human trials and provide preclinical proof-of-concept for AT-108 as an off-the-shelf, personalized cancer immunotherapy based on in situ cDC1 reprogramming."

IO biomarker • Preclinical • Oncology • BATF3 • CD40 • CD8 • IRF8

AT-108, an adenoviral vector based therapy for in situ cancer to dendritic cell reprogramming, leads to durable antitumor activity as a single agent and in combination with immune checkpoint blockade [WITHDRAWN] (ESMO 2025) - No abstract available

Checkpoint block • Checkpoint inhibition • Combination therapy • Viral vector • Oncology

Asgard Therapeutics' study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108 (PRNewswire) - "Novel data shows that AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into an immunogenic cell fate, which mounts strong anti-tumor, antigen-specific responses and durable tumor shrinkage even upon metastatic rechallenge....The study entitled, In vivo dendritic cell reprogramming for cancer immunotherapy, also shows the systematic selection of an optimal delivery system for expression of key reprogramming factors in the tumor, which led to the nomination of Asgard's lead program."

Preclinical • Oncology • Solid Tumor